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background:  CRT is an effective therapy in HF. Pacemakers and defibrillators are implanted for arrhythmogenic indications. Pacing 
dependency can induce HF and is an established CRT upgrade criterion [LVEF<35% and ventricular pacing >40%]. We aimed to compare 
cardiovascular outcomes between upgraded and de-novo CRT’s.
Methods:  A retrospective study of all consecutive CRT implants over five years (Jan 2009 - Dec 2013) in a UK tertiary centre. Data 
was collected on baseline demographics, co-morbidities and indications (NYHA class, ECG, echocardiogram). Comparisons were made 
for these outcomes: acute response [2mths], all-cause mortality and first hospitalisation. CRT response was defined as >1 NYHA class 
increase.
results:  373 CRT implants were performed (79 upgrades). Upgrade and de-novo patients were matched for all comorbidities. Table 1 
demonstrates baseline demographics, indications and CRT response. A Kaplan-Meier analysis was performed on all-cause mortality and 
time to first hospitalisation, with three year rates demonstrated in the table. A significantly worse long-term response (p0.002) and all-cause 
mortality (p0.043) was demonstrated for upgrade patients.
Conclusion:  Upgraded CRT patients have a worse long-term response and higher all-cause mortality. The potential worse outcome for 
upgrade patients should be considered before implant.
HF = Heart Failure, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, ECG = Electrocardiogram
Table 1
 
Total Cohort
N=373
Upgrades
N= 79
De Novo Implants 
N=294 P value
Age (mean+/-SD) 72.0+/-10.4 74.0 +/- 10.6 71.44 +/- 10.4 0.055
Gender (male n,%) 287 (76.9%) 69 (87.3%) 218 (74.1%) 0.013
Device (CRT-D n,%) 182 (48.8%) 39 (49.4%) 143(48.6%) 0.909
NYHA Class 3/4 (n,%)* 324 (91.5%) 74(98.7%) 250 (90.0%) 0.028
LVEF <35% (n,%)* 364 (98.4%) 76(97.4%) 288(98.6%) 0.458
QRS >150msec (n,%)* 272 (77.1%) 55 (78.6%) 217 (76.7%) 0.634
Acute Response (n,%) 132 (61.4%) 23 (59.0%) 109 (61.9%) 0.731
Long-term Response (n,%) 101 (47.0%) 11 (25.6%) 90(52.3%) 0.002
All-Cause Mortality Rate
(36 months) (%+/-SE) 21.1%+/-2.6% 25.6%+/-5.8% 19.2%+/-2.9% (Log-Rank) 0.043
All-Cause First Hospitalisation (36 months) 
(%+/-SE) 42.9%+/-3.3% 46.7%+/-3.7 % 41.9%+/-4.2 % (Log-rank)0.096
*Percentage represents all recorded data
